CD Skripsi
Efek Inhibitor Proteasom Terhadap Histopatologi Perlemakan Hati Pada Tikus Model Aterosklerosis
Atherosclerosis is an inflammatory process that mainly affects the medium
sized arteries. Fatty liver is associated with atherosclerosis, although the
mechanism is not clearly known. One of these conditions is based on increased
levels of oxidative stress and inflammation. Proteasom is a complex enzyme that
plays a vital role in the inflammatory of atherosclerosis. The purpose of this study
is to analyze the effects of proteasome inhibitor namely bortezomib on fatty liver
histopathology in atherosclerosis model rats. This experimental study used 18 rats
(Rattus novergicus) of male Wistar strains. There were 3 treatment groups, which
were the control group (I), the atherosclerosis group (II), and the atherosclerosis
group with bortezomib (III). Atherosclerosis model was obtained by giving
vitamin D3 (700,000 IU/kg) on the first day, followed by atherogenic feed (2%
cholesterol, 0.2% cholic acid, 5% goat fat) for 4 days. Bortezomib (50 μg/weight)
was given intraperitoneally twice, on first day and third day. The evaluation of
liver histopathology using a scoring system to evaluate fatty liver that occurs. The
results showed that the highest fatty liver was in the atherosclerosis group (group
II), which was 38.33% and the lowest in the control group (group I), which was
5.83%. There was a decrease in fatty liver with bortezomib (group III), which was
29.17% and this decrease was statistically significant. It can be concluded that
giving bortezomib 50 μg/weight to atherosclerosis model rats can reduce the
occurrence of fatty liver.
Keywords : atherosclerosis, bortezomib, fatty liver, proteasome
Tidak tersedia versi lain